Drugs that contain Cannabidiol
1. Epidiolex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10195159 | JAZZ PHARMS RES | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(1 year, 11 months ago) | |
| US11096905 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11207292 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956185 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11311498 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10137095 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10603288 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709671 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11766411 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709673 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956183 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956184 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11154516 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11633369 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11357741 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11446258 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10111840 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10849860 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11701330 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709674 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10966939 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956186 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10092525 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9949937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11400055 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11065209 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US10918608 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11160795 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
| US11406623 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| M(M-270) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| New Patient Population(NPP) | Jul 31, 2023 |
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for ...
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
